Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01972529




Registration number
NCT01972529
Ethics application status
Date submitted
24/10/2013
Date registered
30/10/2013
Date last updated
27/02/2018

Titles & IDs
Public title
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
Scientific title
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
Secondary ID [1] 0 0
2013-000965-34
Secondary ID [2] 0 0
E5501-G000-310
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Thrombocytopenia Associated With Liver Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 0 0 0 0
Liver
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - avatrombopag (lower baseline platelet count)
Treatment: Drugs - placebo (lower baseline platelet count)
Treatment: Drugs - avatrombopag (higher baseline platelet count)
Treatment: Drugs - placebo (higher baseline platelet count)

Experimental: Group A (avatrombopag, lower baseline platelet count) - 60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5

Placebo comparator: Group B (placebo, lower baseline platelet count) - placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5

Experimental: Group C (avatrombopag, higher baseline platelet count) - 40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5

Placebo comparator: Group D (placebo, higher baseline platelet count) - placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5


Treatment: Drugs: avatrombopag (lower baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets)

Treatment: Drugs: placebo (lower baseline platelet count)
60 mg placebo (3 x 20 mg matching placebo tablets)

Treatment: Drugs: avatrombopag (higher baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets)

Treatment: Drugs: placebo (higher baseline platelet count)
40 mg placebo (2 x 20 mg matching placebo tablets)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure
Timepoint [1] 0 0
Baseline (Visit 2) up to 7 days following a scheduled procedure
Secondary outcome [1] 0 0
Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on the Scheduled Procedure Day
Timepoint [1] 0 0
Day 10 to Day 13 (Visit 4)
Secondary outcome [2] 0 0
Change From Baseline in Platelet Count on the Scheduled Procedure Day
Timepoint [2] 0 0
Baseline (Visit 2) to Procedure Day 10 to Day 13 (Visit 4)

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Participants greater than or equal to 18 years of age at Screening with chronic liver disease
2. Participants who have a mean baseline platelet count of less than 50 x 10^9/L. Platelet counts must be measured on 2 separate occasions, during the Screening Period and at Baseline, and must be performed at least one day apart with neither platelet count greater than 60 x 10^9/L. The mean of these 2 platelet counts (mean baseline platelet count) will be used for entry criteria and for assignment to the low or high baseline platelet count cohort.
3. Participants scheduled to undergo a permitted elective procedure who, in the opinion of the investigator, will require a platelet transfusion to address a risk of bleeding associated with the procedure unless there is a clinically significant increase in platelet count from baseline
4. Model For End-stage Liver Disease (MELD) score less than or equal to 24 at Screening
5. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to Screening
6. Provide written informed consent
7. Willing and able to comply with all aspects of the protocol
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

1. Any history of arterial or venous thrombosis, including partial or complete thrombosis
2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening
3. Portal vein blood flow velocity rate <10 centimeters/second at Screening
4. Hepatic encephalopathy that cannot be effectively treated
5. Participants with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C or D
6. Platelet transfusion or receipt of blood products containing platelets within 7 days of Screening. However packed red blood cells are permitted.
7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil, and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg, tirofiban) within 7 days of Screening
8. Use of erythropoietin stimulating agents within 7 days of Screening
9. Interferon (IFN) use within 14 days of Screening
10. Estrogen-containing hormonal contraceptive or hormone replacement therapy use within 30 days of Screening
11. Active infection requiring systemic antibiotic therapy within 7 days of Screening. However, prophylactic use of antibiotics is permitted.
12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
13. Elective procedure performed prior to Visit 4 (Procedure Day)
14. Known to be human immunodeficiency virus positive
15. Any clinically significant acute or active bleeding (eg, gastrointestinal, central nervous system)
16. Known history of any primary hematologic disorder (eg, immune thrombocytopenic purpura, myelodysplastic syndrome)
17. Known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden; prothrombin G20210A; ATIII deficiency, etc.)
18. Participants with a history of significant cardiovascular disease (eg, congestive heart failure New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, and coronary artery bypass grafting)
19. Females of childbearing potential who have had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a progesterone-only contraceptive implant/injection, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. All females will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 1 month before dosing.
20. Females who are lactating or pregnant at Screening or Baseline (as documented by a positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
21. Post liver transplant participants
22. Any participant who has previously received avatrombopag
23. Hypersensitivity to avatrombopag maleate or any of its excipients
24. Hemoglobin levels = 8.0 or = 18.0 g/dL for men and > 15 for women at Screening, with hematocrit = 54% for men and = 45% for women
25. Current malignancy including solid tumors and hematologic malignancies (except HCC)
26. Any history of concomitant medical condition that, in the opinion of the investigator(s), would compromise the participant's ability to safely complete the study
27. Currently enrolled in another clinical trial with any investigational drug or device within 30 days of Screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/02/2017
Sample size
Target
Accrual to date
Final
231
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
- Camperdown
Recruitment hospital [2] 0 0
- Adelaide
Recruitment hospital [3] 0 0
- Bedford Park
Recruitment postcode(s) [1] 0 0
- Camperdown
Recruitment postcode(s) [2] 0 0
- Adelaide
Recruitment postcode(s) [3] 0 0
- Bedford Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Louisiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Minnesota
Country [6] 0 0
United States of America
State/province [6] 0 0
Mississippi
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Argentina
State/province [10] 0 0
Buenos Aires
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad Autonoma Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Mendoza
Country [13] 0 0
Austria
State/province [13] 0 0
Linz
Country [14] 0 0
Austria
State/province [14] 0 0
Vienna
Country [15] 0 0
Austria
State/province [15] 0 0
Wien
Country [16] 0 0
Belgium
State/province [16] 0 0
Bruxelles
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
Brazil
State/province [18] 0 0
Rio Grande Do Sul
Country [19] 0 0
Brazil
State/province [19] 0 0
Sao Paulo
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Chile
State/province [21] 0 0
La Serena
Country [22] 0 0
Chile
State/province [22] 0 0
Santiago
Country [23] 0 0
China
State/province [23] 0 0
Hunan
Country [24] 0 0
China
State/province [24] 0 0
Jiangsu
Country [25] 0 0
China
State/province [25] 0 0
Shanghai
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
France
State/province [27] 0 0
Bas Rhin
Country [28] 0 0
France
State/province [28] 0 0
Isere
Country [29] 0 0
France
State/province [29] 0 0
Marne
Country [30] 0 0
France
State/province [30] 0 0
Puy De Dome
Country [31] 0 0
France
State/province [31] 0 0
Somme
Country [32] 0 0
France
State/province [32] 0 0
Vandoeuvre les Nancy
Country [33] 0 0
Germany
State/province [33] 0 0
Baden Wuerttemberg
Country [34] 0 0
Germany
State/province [34] 0 0
Nordrhein Westfalen
Country [35] 0 0
Germany
State/province [35] 0 0
Schleswig Holstein
Country [36] 0 0
Germany
State/province [36] 0 0
Hamburg
Country [37] 0 0
Hungary
State/province [37] 0 0
Bekescsaba
Country [38] 0 0
Hungary
State/province [38] 0 0
Budapest
Country [39] 0 0
Hungary
State/province [39] 0 0
Dunaujvaros
Country [40] 0 0
Hungary
State/province [40] 0 0
Gyula
Country [41] 0 0
Hungary
State/province [41] 0 0
Kaposvar
Country [42] 0 0
Hungary
State/province [42] 0 0
Kecskemet
Country [43] 0 0
Hungary
State/province [43] 0 0
Szombathely
Country [44] 0 0
Hungary
State/province [44] 0 0
Zalaegerszeg
Country [45] 0 0
Italy
State/province [45] 0 0
Foggia
Country [46] 0 0
Italy
State/province [46] 0 0
Bari
Country [47] 0 0
Italy
State/province [47] 0 0
Bologna
Country [48] 0 0
Italy
State/province [48] 0 0
Genova
Country [49] 0 0
Italy
State/province [49] 0 0
Milano
Country [50] 0 0
Italy
State/province [50] 0 0
Modena
Country [51] 0 0
Italy
State/province [51] 0 0
Palermo
Country [52] 0 0
Italy
State/province [52] 0 0
Udine
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Gangwon-do
Country [54] 0 0
Korea, Republic of
State/province [54] 0 0
Gyeonggi-do
Country [55] 0 0
Korea, Republic of
State/province [55] 0 0
Gyeongnam
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Jeollanam-do
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Busan
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Daegu
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Incheon
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Poland
State/province [61] 0 0
Katowice
Country [62] 0 0
Poland
State/province [62] 0 0
Lodz
Country [63] 0 0
Poland
State/province [63] 0 0
Myslowice
Country [64] 0 0
Poland
State/province [64] 0 0
Szczecin
Country [65] 0 0
Poland
State/province [65] 0 0
Wroclaw
Country [66] 0 0
Portugal
State/province [66] 0 0
Coimbra
Country [67] 0 0
Portugal
State/province [67] 0 0
Lisboa
Country [68] 0 0
Portugal
State/province [68] 0 0
Porto
Country [69] 0 0
Portugal
State/province [69] 0 0
Viana do Castelo
Country [70] 0 0
Portugal
State/province [70] 0 0
Vila Real
Country [71] 0 0
Portugal
State/province [71] 0 0
Viseu
Country [72] 0 0
Spain
State/province [72] 0 0
Barcelona
Country [73] 0 0
Spain
State/province [73] 0 0
Pontevedra
Country [74] 0 0
Spain
State/province [74] 0 0
Sevilla
Country [75] 0 0
Spain
State/province [75] 0 0
Valencia
Country [76] 0 0
Spain
State/province [76] 0 0
Valladolid
Country [77] 0 0
Taiwan
State/province [77] 0 0
Kaohsiung
Country [78] 0 0
Taiwan
State/province [78] 0 0
Taichung
Country [79] 0 0
Taiwan
State/province [79] 0 0
Tainan
Country [80] 0 0
Taiwan
State/province [80] 0 0
Taipei
Country [81] 0 0
Taiwan
State/province [81] 0 0
Taoyuan City
Country [82] 0 0
Thailand
State/province [82] 0 0
Bangkok
Country [83] 0 0
Thailand
State/province [83] 0 0
Chiang Mai
Country [84] 0 0
Thailand
State/province [84] 0 0
Pathumthani
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Cornwall
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Greater London
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Greater Manchester
Country [88] 0 0
United Kingdom
State/province [88] 0 0
West Midlands
Country [89] 0 0
United Kingdom
State/province [89] 0 0
West Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eisai Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01972529